EuroAPI's site in Brindisi, Italy (Credit: EuroAPI)
February 29, 2024 12:39 PM ESTUpdated 05:37 PM
Manufacturing

Eu­roAPI’s blue­print for ‘lean­er’ op­er­a­tions in­cludes drop­ping prod­ucts, po­ten­tial lay­offs and sites put on ice

Anna Brown

News Reporter

Eu­roAPI is count­ing on 2024 to be its “year of tran­si­tion” as the small mol­e­cule pro­duc­er plans to dis­con­tin­ue API as­sets, po­ten­tial­ly make lay­offs and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times